Clinical ink is the global life science company that brings data, technology, and patient science together.

Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials.

By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.

For more information, visit www.clinicalink.com



Clinical ink

110 Gibraltar Road, Suite 150

Horsham, PA 19044


Phone: 336-714-7402 ext. 722

Contact: Nina Pruitt


  • A leading pharma company was planning a Phase III trial for a SARS-CoV-2 prophylactic therapy and needed to evaluate post-exposure prophylaxis and preemptive treatment in 1,000+ patients at 82 sites. Explore how eSource was rapidly deployed for clinical trial success.

  • Learn how a purpose-built solution designed to overcome the significant, but typical, challenges of a complex GI trial enables improved trial conduct and a better deployment experience.

  • Academic researchers and two biopharma leaders teamed up with Clinical ink in the WATCH-PD Study to test the power of at-home mobile devices to assess Parkinson’s Disease progression. The work, described here, is an important step in seeking regulators’ qualification of novel digital assessments in early Parkinson’s Disease.

  • eCOA translations don’t have to be overly complicated or time-consuming. When vendors work together, they create efficiencies that benefit both the sponsor and the patients. This article explains how translation specialist RWS and Clinical Ink collaborated to create a new tool that streamlines review and approval of translated eCOA screens.

  • In order to ensure a fluid experience for a patient, usability testing is a critical data point to consider. Addressing both a patient’s needs and access to a digital platform is key to data collection. TransPerfect, along with our partners from Parexel, Clinical Ink, and Health Psychology Research, recently published a poster at the Virtual ISPOR Europe 2020 conference that reviews the impact of moving from in-person to electronic data collection.


  • Clinical ink offers a best-in-class analytics platform to support the development and evaluation of digital biomarkers in clinical trials. 

  • Deploy a smarter, faster, simpler eCOA with Clinical ink, powered by deep outcomes science expertise across many therapeutic areas.

  • Lupus is a complicated disease, characterized by an aggregation of symptoms, which can vary from patient to patient and makes diagnosis difficult. For clinical research, this variability in the manifestation of the disease also increases complexity of data collection. Documentation requirements for a lupus research study are extensive – far more than a typical patient medical chart. And data variability can obscure the ability to detect improvement in disease activity.

  • In this video, see firsthand fit-for-purpose mobile assessments and applications designed to measure endpoints in Parkinson’s Disease. 

  • Parkinson's research is evolving, with a dramatic increase in patient involvement, advanced systems of measurement, and real-world data gathering at the forefront. Subjective assessments and endpoints can now be augmented with richer data sources gathered directly via wearables, sensors, and mobile technology. Beyond enabling data collection outside the clinic, these models, tied to existing gold standard measurements, enhance all stakeholders' abilities to access more sensitive, frequent, and objective measures of Parkinson’s progression.